Growth factors and their receptors in pancreatic cancer

Teratogenesis Carcinogenesis and Mutagenesis

Volumn 21, Issue 1, 2001, Pages 27-44

  Pour, Parviz M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Growth factors (transforming growth factor beta, epidermal growth factor, fibroblast growth factor, nerve growth factor, platelet derived growth factor, insulin like growth factor); Pancreatic cancer

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN P53; SMAD PROTEIN; SMAD4 PROTEIN; SMAD6 PROTEIN; SMAD7 PROTEIN; SOMATOMEDIN; SOMATOMEDIN RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER INHIBITION; CANCER SURVIVAL; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; INDUSTRIALIZATION; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS;

ADENOCARCINOMA; APOPTOSIS; GROWTH SUBSTANCES; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 0035177036     PISSN: 02703211     EISSN: None     Source Type: Journal    
DOI: 10.1002/1520-6866(2001)21:1<27::AID-TCM4>3.0.CO;2-9     Document Type: Article

References (139)

1. Pancreatic carcinoma
2. Cancer statistics. 1997
3. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: Luorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin, and mitomycin
4. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group
5. Chemoradiotherapy in the management of localized tumors of the pancreas
6. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas
7. Treatment strategy for pancreatic head cancer: Pylorus-preserving pancreatoduodenectomy, intraoperative radiotherapy and portal catheterization
8. Surgery and multimodal treatments in pancreatic cancer: A review on the basis of future multimodal treatment concepts
9. Treatment with an LHRH analogue in patients with advanced pancreatic cancer: A preliminary report
10. Influence of sex hormones on pancreatic cancer
11. LH-RH receptors in the human pancreas: Basis for antihormonal treatment in ductal carcinoma of the pancreas
12. Treatment of duct carcinoma of the pancreas with the LH-RH analogue buserelin
13. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer
14. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer
15. TGF-beta signal transduction
16. TGF-beta receptor signaling
17. TGF-beta signalling from cell membrane to nucleus through SMAD proteins
18. Expression cloning and characterization of the TGF-beta type III receptor
19. Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-beta receptor system
20. A human Mad protein acting as a BMP-regulated transcriptional activator
21. Smads: Transcriptional activators of TGF-beta responses
22. SMADs: Mediators and regulators of TGF-beta signaling
23. Signal transduction. Feedback from inhibitory SMADs
24. Dual role of the Smad4/DPC4 tumor suppressor in TGFbeta-inducible transcriptional complexes
25. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
26. Smad6 inhibits BMP/Smad1 signaling by specifically competing with the Smad4 tumor suppressor
27. Smad6 inhibits signalling by the TGF-beta superfamily
28. The TGF-beta family mediator Smadl is phosphorylated directly and activated functionally by the BMP receptor kinase
29. Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2
30. Smadl and smad5 act downstream of intracellular signalings of BMP-2 that inhibits myogenic differentiation and induces osteoblast differentiation in C2C12 myoblasts
31. Cloning and overexpression of TGF-beta 1 cDNA in a mammary adenocarcinoma: In vitro and in vivo effects
32. Differential localization of transforming growth factor-beta isoforms in human gastric mucosa and overexpression in gastric carcinoma
33. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival
34. Attenuated ALK5 receptor expression in human pancreatic cancer: Correlation with resistance to growth inhibition
35. Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-betal in COLO-357 cells
36. Induction of p21waf1 expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells
37. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression
38. Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage
39. Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer
40. Dpc4 transcriptional activation and dysfunction in cancer cells
41. Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways
42. DPC4 gene in various tumor types
43. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas
44. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells
45. A transforming growth factor beta receptor type II gene mutation common in colon and gastric but rare in endometrial cancers with microsatellite instability
46. Mutation of the transforming growth factor-beta type II receptor gene in right-sided colorectal cancer: Relationship to clinicopathological features and genetic alterations
47. Mutation of the type II transforming growth factor-beta receptor is coincident with the transformation of human colon adenomas to malignant carcinomas
48. Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer
49. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer
50. Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer
51. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo
52. The epidermal growth factor family
53. Epidermal growth factor is a major growth-promoting agent in human milk
54. A physiological role of epidermal growth factor in male reproductive function
55. The epidermal growth factor: A review of structural and functional relatlonships in the normal organism and in cancer cells
56. Neuregulin-2, a new ligmand of ErbB3/ErbB4-receptor tyrosine kinases
57. Ligands for ErbB-family receptors encoded by a neuregulin-like gene
58. Structure and function of heparin-binding EGF-like growth factor (HB-EGF)
59. The physiology of transforming growth factor-alpha
60. TGF alpha in normal physiology
61. The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity
62. Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF family
63. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family
64. Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4
65. Molecular cloning and sequencing of an intron of Her2/neu (ERBB2) gene
66. The type 1 (EGFR-related) family of growth factor receptors and their ligands
67. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors
68. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling
69. Growth factor signaling by receptor tyrosine kinases
70. SH2 and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins
71. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein
72. Inhibition of the MAP kinase cascade blocks heregulin-induced cell cycle progression in T-47D human breast cancer cells
73. ErbB kinases and NDF signaling in human prostate cancer cells
74. Specificity within the EGF family/ErbB receptor family signaling network
75. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas
76. Secondary dimerization between members of the epidermal growth factor receptor family
77. The actin binding domain of the epidemlal growth factor receptor is required for EGF-stimulated tissue invasion
78. Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras
79. The neurotrophic action and signalling of epidermal growth factor
80. Parallel signal processing among mammalian MAPKs
81. Dynamics and organization of MAP kinase signal pathways
82. MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: Upstream regulators of the c-Jun amino-terminal kinases?
83. The TAO of MEKK
84. The MAPK signaling cascade
85. Enhanced erbB-3 expression in human pancreatic cancer correlates with tumor progression
86. Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer
87. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha
88. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
89. Role of growth factors in pancreatic cancer
90. Growth factors and oncogenes in pancreatic cancer
91. Induction and expression of amphiregulin in human pancreatic cancer
92. Betacellulin, a member of the epidermal growth factor family, is overexpressed in human pancreatic cancer
93. Overexpression of HER2/neu oncogene in human pancreatic carcinoma
94. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer
95. Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice
96. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum
97. The FGF family of growth factors and oncogenes
98. Signaling molecules that mediate the actions of FGF
99. Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity
100. Structural and functional diversity in the FGF receptor multigene family
101. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis
102. Structural and functional specificity of FGF receptors
103. Molecular versus conventional markers in pancreatic cancer, Digestion
104. Fibroblast growth factor-5 stimulates mitogenic signaling and is overexpressed in human pancreatic cancer: Evidence for autocrine and paracrine actions
105. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage
106. Overexpresslon of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage
107. Increased expression of keratinocyte growth factor in human pancreatic cancer
108. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer
109. Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines
110. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas
111. The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer
112. Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer
113. Suppression of fibroblast growth factor receptor signaling inhibits pancreatic cancer growth in vitro and in vivo
114. The nerve growth factor 35 years later
115. Nerve growth factor as a mitogen for a pancreatic carcinoid cell line
116. Nerve growth factor stimulates clonal growth of human lung cancer cell lines and a human glioblastoma cell line expressing high-affinity nerve growth factor binding sites involving tyrosine kinase signaling
117. Nerve growth factor stimulates in vitro invasive capacity of DU145 human prostatic cancer cells
118. The trk proto-oncogene encodes a receptor for nerve growth factor
119. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF
120. Patterns of growth and metastases of induced pancreatic cancer in relation to the prognosis and its clinical implications
121. Cancer of the pancreas. 50 years of surgery
122. Morphology of pancreatic cancer: Involvement of nerves
123. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer
124. Platelet-derived growth factor in autocrine transformation
125. Platelet-derived growth factor: Mechanism of action and possible in vivo function
126. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer
127. Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles
128. Insulin-like growth factors and breast cancer
129. Novel aspects of the insulin-like growth factor binding proteins
130. Molecular aspects of insulin-like growth factors, their binding proteins and receptors
131. Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGF-binding proteins-l-6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries
132. Insulin-like growth factor binding proteins in the human circulation: A review
133. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit
134. An insulin-like growth factor (IGF) binding protein enhances the biologic response to IGF-I
135. Insulin-like growth factor I and transforming growth factor alpha as autocrine growth factors in human pancreatic cancer cell growth
136. Serum levels of insulin-like growth factors (IGF-I and IGF-II) and their binding protein (IGFBP-3) are not elevated in pancreatic cancer
137. Altered expression of insulin-like growth factor II receptor in human pancreatic cancer